Today, everyone knows about such a pathology as COVID-19 - both children and adults. We are talking about an infectious disease that is provoked by the SARS-CoV-2 coronavirus, identified in 2019 and becoming a universal problem on the planet. After the pandemic was declared, the main task of scientists was to create a vaccine that protects people from infection, as well as to develop the most effective treatment for the disease. Vaccination was soon launched, but until now nothing was known about new effective drugs. COVID-19 was treated mainly with medications such as Tamiflu, Dexamethasone (corticosteroid), Bamlanivimab, Kazirivimab and Imdevimab (monoclonal antibodies), Avigan (Favilavir), Ivermectin, etc. Effects, sometimes quite serious.
More recently, Australian scientists have given new hope to the world by announcing the creation of a long-awaited drug. The new drug not only alleviates the symptoms of coronavirus infection, but reduces the presence of the virus in the body by 99.9%. Experts have already successfully tested the drug on rodents in a laboratory.
The new drug was developed in close collaboration with the City of Hope Cancer and Diabetes Research Center and the Griffith University Institute of Health. Scientists explain: the created drug cures coronavirus infection, and not only speeds up recovery. The basic composition of the drug is due to the use of miRNA (small interfering RNA) technology, which can directly affect the viral genome and cause its death. As a result, the pathogen completely loses its ability to reproduce.
Test tests on rodents have shown that treatment with miRNA technology dramatically reduces the level of the viral pathogen in the body by almost 100%. In addition, the base of the therapeutic drug can be stored for up to 12 months at + 4 ° C, and up to 4 weeks at room temperature.
Professor Macmillan, who took part in the creation of the drug, draws attention to the fact that the use of new technology has led to the complete recovery of experimental rodents. Moreover, after the treatment, it was not possible to detect the virus in their lungs.
The developed tool can be called universal: it acts on the entire range of beta-coronaviruses, including the SARS-CoV-1 virus, SARS-CoV-2, as well as other variations that may appear in the future.
Researchers have every reason to believe that the created drug can soon be used in therapeutic regimens for patients with coronavirus infection. At the moment, scientists are starting to conduct tests with the participation of volunteers.
The results of the work are published on the Griffith University page